tiprankstipranks
Percheron Therapeutics (AU:PER)
ASX:PER
Australian Market

Percheron Therapeutics (PER) Income Statement

Compare
12 Followers

Percheron Therapeutics Income Statement

Last quarter (Q4 2022), Percheron Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Percheron Therapeutics's net income was $―. See Percheron Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Jun 22Jun 21Jun 20Jun 19Jun 18
Total Revenue
$ ―$ ―$ ―$ ―$ ―
Gross Profit
$ ―$ ―$ ―$ ―$ ―
Operating Expenses
$ ―$ ―$ ―$ ―$ ―
Depreciation and Amortization
$ 89.22K$ 103.32K$ 107.60K$ 5.38K$ 6.41K
EBITDA
$ -7.52M$ -8.58M$ -6.56M$ -3.58M$ -2.61M
Operating Income
$ -7.61M$ -8.68M$ -6.67M$ -3.58M$ -2.62M
Other Income/Expenses
$ ―$ ―$ ―$ ―$ ―
Pretax Income
$ ―$ ―$ ―$ ―$ ―
Net Income
$ -5.81M$ -8.06M$ -5.91M$ -2.94M$ -2.33M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ ―$ ―$ ―$ ―$ ―
Diluted EPS
$ ―$ ―$ ―$ ―$ ―
Weighted Average Shares Outstanding
Weighted Average Shares Outstanding (Diluted)
Currency in USD

Percheron Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis